Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report

Results from the REMAP-CAP trial show that in adults commencing organ support in ICU, tocilizumab (n=353) and sarilumab (n=48) improved days free of organ support (median 10 and 11 vs 0 with control) and in-hospital mortality (28% and 22.2% vs 35.8%).

SPS commentary:

On 8th January, the MHRA published an Interim Position Statement advising clinicians to consider prescribing IV tocilizumab (sarilumab is an alternative if available) following the defined criteria, on the basis of these findings. Work is now underway to develop a UK clinical commissioning policy for tocilizumab and sarilumab, which will be based on a NICE review of the available research evidence. 

MedRxiv

Resource links:

Interim Position Statement